Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WAY-151693 is a synthetic small molecule belonging to the sulfanilide class of organic compounds. It is a sulfonamide derivative of a hydroxamic acid and acts as a potent and selective inhibitor of human collagenase-3, also known as matrix metalloproteinase 13 (MMP-13). The compound binds to the active site of MMP-13, inhibiting its enzymatic activity. MMP-13 plays an important role in the degradation of extracellular matrix components such as collagen, which is relevant in various pathological processes including arthritis and cancer metastasis. WAY-151693 has been studied primarily in structural biology and drug design research settings but has not advanced into clinical development for any therapeutic indication[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WAY-151693.